Movement Alert｜Natera Intraday Rise 3.01% in Regular Trading, analyst initiation and target-price increases support sentiment

Market Focus10-28 21:55

On October 28, Natera recorded an Intraday Rise of 3.01% in Regular Trading, trading at $424.295 per share, with turnover of $47.2913 million.

The clearest recent catalyst is an analyst initiation from October 23, when Roth Capital began coverage with a Buy rating and a $475 price target, above the then-consensus target of $387.52. That followed Morgan Stanley's October 12 target increase to $435 from $355 while maintaining an Overweight rating.

Recent company-specific developments also reinforced the constructive backdrop. On October 9, Natera said its multi-cancer early detection assay received FDA Breakthrough Device Designation, a step intended to accelerate development and review. Earlier in the month, the company also announced new Signatera-related clinical trial activity in melanoma and breast cancer, adding to momentum around its oncology franchise.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment